Mankind Pharma Ltd. Company History and Annual Growth Details

The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name “Mankind Pharma Private Limited”, pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi (“RoC”). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to “Mankind Pharma Limited” and the RoC issued a fresh certificate of incorporation on April 13, 2006.

Major events and milestones:

2004 

-Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets amongst others

2005 

-Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh

-Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others

2007 

-Entered the consumer healthcare segment with the launch of ‘Manforce’ brand

-Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst othersRaised Rs.720 million from Monet Limited

2009 

-Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh

2010 

-Launched ‘Preganews’ brand in the consumer healthcare segment

2012 

-Setup the first R&D centre at IMT Manesar, Haryana

2014 

-Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)

-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh

2015 

-Incorporated the Subsidiary, Lifestar Pharma LLC in the US

-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore

2017 

-Set up the manufacturing facility in Sikkim

2018 

-The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time

2019 

-Entered the female infertility segment with the launch of ‘Dydroboon’ tablets

2020 

-Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal

-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets

-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets

2021 

-Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE

-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets

-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets

2022 

-Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited

-Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others

-Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others

-Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories

-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.

-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.

-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.

-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.

2024

-Mankind Pharma Completes Landmark Acquisition of BSV.

-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.

-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.

-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).

2025

-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited  and Jaspack Industries Private Limited  with Mankind Pharma Limited